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Abstract
Intracranial plasmacytomas are an uncommon presentation of extramedullary relapse of multiple
myeloma. The optimal management of extramedullary plasmacytomas remains unclear, with initial
reports of bortezomib showing promising clinical results. We describe a case of multiple
extracellular, including intracranial, plasmacytoma, with no evidence of marrow involvement, in
a patient with relapsed IgA multiple myeloma. To our knowledge, this is the first reported case of
a patient with rapid extramedullary relapse of disease despite recent exposure to bortezomib and
dexamethasone.
Case presentation
A 64 year old female patient consulted her ophthalmo-
logist because of onset of blurred vision. This diplopia was
worse on looking straight ahead, and to the left. Initially,
intermittent, the diplopia became constant, at which point
she attended her ophthalmologist. She denied any other
symptom.
Physical examination revealed a primary position eso-
tropia, binocular horizontal diplopia and a horizontal
gaze-evoked nystagmus. These findings were consistent
with a left sixth cranial nerve palsy. Notably, additional
signs of increased ICP (e.g. papilloedema) were absent
and the remaining neurological examination was
unremarkable.
This lady was diagnosed with IgA Multiple Myeloma
(MM) in 2004, for which she commenced treatment with
thalidomide and dexamethasone. This was discontinued
after three cycles, due to proximal myopathy. She then
received melphalan and prednisolone as second-line
treatment, with suppression of serum monoclonal band.
An elective autologous stem cell transplant (ASCT), with
cyclophosphamide pre-conditioning, was performed in
2005. A subsequent disease relapse two years later was
initially treated with melphalan and prednisolone, but
this regimen was complicated by pancytopaenia. At this
point, bortezomib and dexamethasone therapy was
commenced, with an excellent response [1,2]. Bortezo-
mib was administered as eight 3-week treatment cycles of
bortezomib (1.3 mg/m2 as a single intravenous bolus on
Page 1 of 4
(page number not for citation purposes)
days 1, 4, 8, 11) followed by a 10-day rest period (days 12
through 21). In addition, the patient received dexa-
methasone 20 mg orally once daily on the day of
bortezomib injection and the day thereafter (days 1, 2,
4, 5, 8, 9, 11, and 12). An SPEP on completion of this
chemotherapy, one month prior to this presentation,
demonstrated complete suppression of serum parapro-
tein, although B2 microglobulin was slowly rising
(2.66 mg/L).
On admission, MRI brain demonstrated enhancing
meningeal-based lesions in the left frontal region and
the left side of the cavernous sinus (Figure 1a and b).
Immunofixation electrophoresis demonstrated an IgA-
lambda monoclonal band, with free lambda chain
measuring 142 mg/dl. Subsequent CT TAP demonstrated
multiple pelvic osseous lytic lesions as well as paraverteb-
ral and pleural basedmasses (Figure 2). Notably, there was
no increase of plasma cells in bone marrow.
A diagnosis of extramedullary relapsed MM (paravertebral,
pleural and intracranial masses) after recent bortezomib
therapy was made.
Discussion
We describe a case of multiple extracellular plasmacytoma,
with no evidence of marrow involvement, in a patient
with relapsed IgA MM. To our knowledge, this is the first
reported case of a patient with rapid extramedullary
relapse of disease despite recent exposure to bortezomib
and dexamethasone.
While rare, extramedullary relapse of MM following ASCT
has previously been reported, with a rate of relapse of
14% in the Spanish Registry of Transplants.[3] When
relapse does occur, prognosis is poor, with mortality of
73%, and median survival of 12 months [4]. Intracranial
plasmacytomas are rare, with the Arkansas group demon-
strated an incidence of CNS involvement in 1% of relapse
after ASCT [5]. Intracranial plasmacytomas without
medullary relapse are even rarer, with only a few reported
cases in the literature [6,7].
The optimal management of extramedullary plasma-
cytomas remains unclear. A 2004 review by the UK
Myeloma Forum of treatment modalities for plasmacy-
toma, either solitary bone or extramedullary, concluded
that while the available evidence was limited, localised
radiotherapy was the favoured treatment option [6]. In
recent times, localised radiotherapy has been largely
superseded by bortezomib, a proteasome inhibitor of
NF-KB, which is now the treatment of choice for
extramedullary disease [8]. Initial reports of bortezomib
for extramedullary MM have shown promising clinical
results [5,9,10].
Figure 1a and b. Magnetic resonance imaging of patient’s
brain shortly after admission. Gadolinium enhanced Magnetic
Resonance Image demonstrating two enhancing meningeal-
based lesions one in the left frontal extra-axial region, and the
second lesion on the left side of the cavernous sinus. The
lesion in the left cavernous sinus is also associated with bone
destruction. Given this patients past medical history, these
images are consistent with extra axial soft tissue deposits
of myeloma.
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Our patient had recently completed a course of borte-
zomib, and despite this, had a rapid presentation with
extramedullary disease. This relapse may suggest a high
degree of chemo-resistance in our patient, a hypothesis
supported by several case reports that propose a high
degree of chemo-resistance in CNS and skull lesions that
precede medullary relapse [7]. Additionally, this lady had
both paravertebral and pleural plasmacytomas. Spinal and
surrounding tissue have been identified as sites of relapse
in many series, leading to the theory of so-called
“sanctuary sites”. Terpos et al have proposed that pre-
conditioning with high dose chemotherapy may permit
the escape, and subclinical seeding, of an extramedullary
clone of plasma cells with extensive chemoresistance [2].
The clinical phenomenon of an extramedullary “escape”
has previously been recognised with thalidomide regimes.
Anagnostopoulos et al. described the occurrence of a
‘hyposecretory’ progression in 48/103 patients, with
reduction of serum paraprotein levels, despite extensive
plasmacytosis of bone marrow. Bone marrow progression
occurred with and without concomitant extramedullary
involvement. This discordance was also identified in two
patients with soft tissue plasmacytomas, and one patient
each with cervical and mediastinal lymph node plasma-
cytomas. As the anti-myeloma mechanisms of thalido-
mide are not fully elucidated, they have suggested that this
treatment allows selection of a more immature clone, and
thus reduced levels of paraprotein [11]. Experience with
thalidomide in the treatment of extramedullary disease
has been disappointing, with suggestions that the stroma
of bone marrow are necessary for its inhibition of plasma
cells [8].
Conclusion
Multiple plasmacytomas, including intracranial involve-
ment, is an uncommon presentation of extramedullary
relapse of MM. Although promising in treating extensive
plasmacytosis of bone marrow, this patient’s clinical
course suggests that bortezomib may not be effective for
treating all extramedullary relapses, or a highly chemo-
resistant clone (as suggested by her extensive prior
treatments).
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